The generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, BTK inhibitors, and innovative CAR-T cell therapies from major pharmaceutical companies.

Scientists at IOB have developed MitoCatch, a breakthrough technology using engineered protein binders to deliver healthy mitochondria directly to damaged cells. The system successfully targets neurons and various other cell types, with donor mitochondria remaining functional and improving cell survival in disease models. This advancement offers a potential new approach for treating mitochondrial diseases and neurodegenerative conditions.

The castration-sensitive prostate cancer (CSPC) market is expected to grow significantly from $5.14 billion in 2025 to $11.75 billion by 2036, driven by an aging population, increased disease awareness, and successive drug approvals. Key therapies like XTANDI and ERLEADA are dominating the market, while newer treatments including PARP inhibitors and radioligand therapies are emerging. Recent approvals and expanded labels for existing drugs are accelerating market growth across major regions.

The SLE and LN market is projected to grow from $2.4 billion in 2024 to $5.9 billion by 2034 (9.6% CAGR), driven by 10 late-stage pipeline drugs offering improved safety and efficacy over current generic treatments. However, growth faces headwinds from biosimilar competition and high treatment costs limiting adoption rates.

Merck reduced its acquisition offer for Terns Pharmaceuticals from $61 to $53 per share after reviewing updated clinical trial data for TERN-701, showing a lower MMR achievement rate than expected. A competing bidder also withdrew its offer due to concerns about the drug's differentiation and risk profile, though Merck maintained enthusiasm for the deal.

President Trump signed an executive order imposing 100% tariffs on imported pharmaceuticals, with 13 drug companies already exempt through Most Favored Nation (MFN) pricing agreements. Companies that signed deals and committed to U.S. manufacturing face 0% tariffs through 2029, while non-signatories face the full 100% levy starting July 31. The tariff threat has triggered over $150 billion in domestic manufacturing investments from deal-signing companies.

Over 120 pharmaceutical companies are actively developing 140+ pipeline drugs for systemic lupus erythematosus (SLE), with approximately 30+ drugs in mid-stage development and 85+ in early stages. Key players include Roche, Biogen, Novartis, AbbVie, and Johnson & Johnson, with promising therapies targeting various mechanisms such as B cell inhibitors, JAK inhibitors, and TLR antagonists. Recent regulatory milestones include FDA Fast Track designation for nipocalimab and Breakthrough Therapy Designation for litifilimab.

The Proleukin market is projected to grow from $1.24 million in 2025 to $1.68 million by 2030, with a CAGR of 6.1%. Growth drivers include rising cancer prevalence, increased cystic fibrosis diagnoses, enhanced R&D investments, and the drug's approval for respiratory and oncology applications. Iovance Biotherapeutics acquired Proleukin in May 2023, strengthening its immunotherapy platform. North America currently leads the market, while Asia-Pacific is expected to be the fastest-growing region.

The American Heart Association has introduced the Cardiovascular-Kidney-Metabolic (CKM) Health Initiative to increase awareness of the interconnected nature of heart disease, kidney disease, diabetes, and obesity. Nearly 90% of U.S. adults have at least one CKM risk factor, yet many cases remain undiagnosed. The initiative encourages regular screening and lifestyle modifications to prevent complications.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet), a biosimilar to Prolia for treating osteoporosis and related bone conditions across all indications. Additionally, the company's proposed biosimilar candidate to Xolair (omalizumab) for allergic asthma and other conditions received filing acceptance from both the U.S. FDA and European EMA. These milestones advance Teva's Pivot to Growth strategy and expand its biosimilars portfolio.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet) biosimilar for treating various bone diseases, and acceptance of regulatory filings for an omalizumab biosimilar candidate by both FDA and EMA. These milestones represent significant progress in Teva's 'Pivot to Growth' strategy to establish itself as a leading biopharmaceutical company with a competitive biosimilar portfolio.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet), a biosimilar to Prolia for treating various bone diseases, and acceptance of regulatory filings for its omalizumab biosimilar candidate to Xolair by both FDA and EMA. These approvals represent significant progress in Teva's 'Pivot to Growth' strategy to expand its biosimilar portfolio.